| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Hans Lennart Rudolf Wigzell is Director at SRPT. Hans Lennart Rudolf Wigzell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $780K at current prices.
Historically, Hans Lennart Rudolf Wigzell's trades have earned a middling insider score of 60/100 across 3 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +21.1%.
The SRPT filings lean toward selling, a net 93,834 shares.
Hans Lennart Rudolf Wigzell has 22 Form 4 filings on record from February 2015 to June 2026, all as Director at Sarepta Therapeutics (SRPT), 2015–2026.
The 47 reported transactions were 15 open-market sales, 12 stock awards, 10 option or other derivative awards and 10 option exercises.
Counted by filing, the open-market trades come to no purchases and 10 sales worth about $11.0M.
The largest open-market sale was 15,000 shares of SRPT at an average $123.25 on March 8, 2024, about $1.8M. Twelve months later SRPT was down 17%.
None of the 3 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2024 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 10,500 | $124.84 | $1,310,820.00 | -31.5% | -19.8% | -82.7% | |
| Mar 8, 2024 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 15,000 | $123.25 | $1,848,795.25 | -39.6% | -5.6% | -17.2% | |
| Aug 4, 2023 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 15,000 | $106.72 | $1,600,800.00 | -41.7% | -26.2% | +36.7% | |
| Mar 8, 2021 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 10,000 | $83.51 | $835,100.00 | -37.7% | - | - | |
| Aug 10, 2020 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 10,000 | $159.00 | $1,590,043.90 | -42.0% | - | - | |
| May 20, 2020 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 5,000 | $150.64 | $753,209.70 | -26.6% | - | - | |
| Mar 4, 2020 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 5,000 | $116.89 | $584,450.00 | -26.6% | - | - | |
| May 23, 2019 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 10,000 | $120.00 | $1,200,000.00 | -46.0% | - | - | |
| Nov 1, 2018 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 6,667 | $140.50 | $936,713.50 | -39.8% | - | - | |
| Nov 30, 2017 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 6,667 | $55.89 | $372,618.63 | -50.0% | - | - |